Ms. Zhang Ying was invited to attend the 2020 DIA and give a keynote speech
In October of the golden autumn, the 2020 DIA Drug Information Annual Conference and Exhibition was grandly held at the International Expo Center by Jinji Lake in Suzhou. This year's DIA Annual Conference featured 15 academic topics, over 90 academic branches, and more than 3000 attendees. Among them, 7 pre conference events in popular fields invited over 100 experts and scholars from all walks of life to gather together to explore, promote pharmaceutical innovation, and facilitate multi-party cooperation.
On October 29th, at the 12th DIA Annual Conference in 2020, Ms. Zhang Ying, co-founder of Ruiyang United Intellectual Property, was invited to give a keynote speech on "Patent Layout, Challenges and Responses of Original Research and Generic Pharmaceutical Companies". She talked about the much higher dependence of patent protection in the pharmaceutical industry than in other industries. Drug patent protection involves multiple dimensions, and it is necessary to establish a pharmaceutical patent protection ecosystem, not only to protect trademark logos, but also to protect compounds, compositions, indications, crystals, preparations, intermediates, preparation process patents, etc.
Zhang Ying also mentioned that in order to safeguard the interests of enterprise researchers and stimulate their innovation enthusiasm, most countries around the world have established drug patent protection systems that are suitable for their own situations. As early as 1984, the United States was the first to establish a complete drug patent protection system with drug patent links, trial data protection, and patent extension as its core, thus promoting the balanced development of its domestic pharmaceutical market. However, China has not yet established a systematic drug patent protection system. Due to the long innovation cycle, high investment costs, and high risks of drugs, if the market cannot bring returns to innovators, their enthusiasm will not be sustainable. Patent protection, as the "armor" of enterprises, not only protects the intellectual property rights of enterprises from infringement, but also enables them to obtain the expected return on research and development of drugs, which in turn nurtures innovation. Therefore, it is urgent to strengthen the construction of the patent protection system。
In today's era where challenges and opportunities coexist, as intellectual property service partners that safeguard China's pharmaceutical and health research and development field, we believe that Ruiyang United Intellectual Property has the ability and confidence to work hand in hand with pharmaceutical enterprises, promote innovative development, and safeguard rights ownership.